Navigation Links
Taro Shareholders to Levitt and Directors: Quit the Board
Date:12/31/2009

MUMBAI, India, Dec. 31 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that based on the count of votes at Taro Pharmaceutical Industries Ltd.'s (Taro) (Pink Sheets: TAROF) annual general meeting, Taro's minority shareholders sent a strong message of disapproval to Barrie Levitt and his continuing control of Taro. Shareholders voted decisively against the election of Taro's external director nominees. In addition, 78% of Taro's minority shareholders, i.e. those not affiliated with the Levitts or Sun, voted against the continued service of the Levitt slate of directors. A similar number voted against the board's indemnification proposals.

"Taro's shareholders have spoken today, clearly and loudly. Taro equity shareholders holding more than two-thirds of its equity want to remove the Levitts and their associates from the board. Ironically, it is these same directors who claim to be protecting minority shareholder interests. It is abundantly clear to the shareholders that the Levitts and Taro directors have misappropriated the minority shareholder protection argument to justify all their illegal actions. With such an unambiguous rejection by minority shareholders, the Levitts and Taro directors now have lost this only crutch," said Dilip Shanghvi, Chairman and Managing Director of Sun Pharmaceuticals.

Despite the clear message from Taro's shareholders, the Levitt family will unfortunately remain in control of Taro, for the time being. This is due to Taro's skewed capital structure, which gives the Levitt family a special class of non-equity shares holding 33 1/3% of the company's voting power. They also used these special non-equity shares to pass a resolution rewarding Taro's independent directors with widely expanded indemnification protection. It is these same directors who have not produced reliable financial statements since 2003 and have permitted the Levitts unhindered use of Taro resources for their narrow personal gains.

Mr. Shanghvi continued, "It is time that the Levitts, who own a mere 12% of Taro's equity, hear the voice of the minority shareholders, in whose interest they claim to be working, and stop relying on their special founder shares to decide who will manage Taro. After watching Taro reach the brink of bankruptcy, seeing their shares delisted from trading, hearing endless false promises about receiving audited financial statements, and witnessing an unchecked drain of company resources, the shareholders have clearly had enough. A board of directors that cannot produce reliable audited financial statements for almost seven years simply should not remain in office."

The Levitt family has a signed contractual obligation to sell its shares to Sun at a pre-defined price. In line with this, Sun opted to buy the Levitt family shares in June 2008. However, the Levitts, with full support of the Taro directors, have prevented the close of this transaction through improper use of Taro resources. Taro directors initiated legal actions, at the company's expense, in order to protect the Levitt family from having to comply with its obligations. The Tel Aviv District Court ruled in favor of Sun in August 2008, and offered harsh criticism of the conduct of Taro's directors (the same directors who were re-elected and rewarded today by the Levitt family). Taro and its directors, under the pretext of protecting the same minority shareholders who have conclusively rejected them today, appealed to the Supreme Court, a decision that is awaited.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

You can also follow us on Twitter.

Contacts


    Uday Baldota
    Tel          +91 22 6645 5645, Xtn 605
    Tel Direct   +91 22 66455605
    Mobile       +91 98670 10529
    E mail       uday.baldota@sunpharma.com

    Brunswick Group for Sun Pharma
    Erin Becker/Nicki Kahner
    +1 212 333 3810

    Arad Communications for Sun Pharma
    Irit Radia
    +972-54-6699311

    Mira Desai
    Tel          +91 22 6645 5645, Xtn 606
    Tel Direct   +91 22 66455606
    Mobile       +91 98219 23797
    E mail       mira.desai@sunpharma.com

    MacKenzie Partners
    Robert Marese
    +1 212 929 5500

    Greenhill
    Ashish Contractor
    +1 212 389 1537

SOURCE Sun Pharmaceutical Industries Ltd.

RELATED LINKS
http://www.sunpharma.com

'/>"/>

SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. Immtech Announces Posting of Annual Shareholders Meeting Presentation
3. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
4. CEL-SCI Corporation Releases Letter to Shareholders
5. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
6. CEL-SCI Corporation Releases Letter to Shareholders
7. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
8. Letter to Shareholders From Imagenetix, Inc. President/CEO William Spencer
9. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Bob McDonald Outlines Key Long Term Growth Strategies To P&G Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... July 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... its second quarter 2017 operating results on Monday, August ... to follow at 5:00 p.m. ET. ... to a live broadcast of the conference call by ... participant code 51641230 approximately 15 minutes prior to the ...
(Date:7/20/2017)... 2017  Prime Therapeutics LLC (Prime) released this statement from ... today,s Institute for Clinical and Economic Review,s (ICER) public ... and value of abuse-deterrent formulations (ADF) of opioids. Prime was ... the meeting. "The ... to the use of abuse-deterrent formulations (ADF) in opioids in ...
(Date:7/14/2017)... VEGAS , July 13, 2017 It should ... United States is in the midst of a ... Control , since 1999, the number of overdose deaths from ... "resulting in over half a million dead from 2001 to ... codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a compelling ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... 2017 , ... Patients with missing teeth now have the ... from Dr. Alejandro Kovacs. Dr. Kovacs is a board-certified periodontist and prosthodontist who ... dental implants in Longview, TX. , During traditional dental implant ...
(Date:7/27/2017)... ... 27, 2017 , ... TransPanel Volume 4 is a collection of animating panel ... exclusive features transitions that contain between 2 and 6 animated panels. Change the direction ... menus. TransPanel Volume 4 makes editing easy in Final Cut Pro X. , TransPanel ...
(Date:7/27/2017)... Clara, CA (PRWEB) , ... July 27, 2017 ... ... announces the addition of a secure cloud-based polysomnography (PSG) distributed scoring solution to ... support accelerated diagnostics and sleep care management. The speed and functionality of scoring ...
(Date:7/27/2017)... ... 2017 , ... SSCI, a division of Albany Molecular Research, ... representing a milestone achievement. , As an industry-leading provider of ... served as expert and fact witnesses to assist our clients to perform infringement ...
(Date:7/27/2017)... ... ... Angeles leg of the US movie premier of the Man in the Camo Jacket will ... Davis Theater inside the Grammy Museum Located in downtown Los Angeles in the LA Live ... musician, Mike Peters (of The Alarm), his rise to fame, battle with cancer and inspiring ...
Breaking Medicine News(10 mins):